Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1986-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/JCEM-63-4-1031PMID 2943752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins

  1985cited by this paper
• Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.

  1985cited by this paper
• Ultrasonic findings in polycystic ovarian disease.

  1985cited by this paper
• Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia.

  1985cited by this paper
• Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men.

  1984cited by this paper
• Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

  1984cited by this paper
• Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.

  1984cited by this paper
• Polycystic ovarian disease: current concepts of pathophysiology and therapy.

  1984cited by this paper
• Polycystic ovarian disease: current concepts of pathophysiology and therapy

  1984cited by this paper
• Treatment of male and female precocious puberty (PP) by monthly injections of a continuous release preparation of D-Trp-6-LH-RH

  1984cited by this paper
• Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.

  1983cited by this paper
• Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.

  1983cited by this paper
• Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.

  1982cited by this paper
• Androgens and progestins in the human ovarian follicle: differences in the evolution of preovulatory, healthy nonovulatory, and atretic follicles.

  1981cited by this paper
• REVIEW ARTICLE: THE POLYCYSTIC OVARY SYNDROME

  1980cited by this paper
• Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol.

  1980cited by this paper
• The polycystic ovary syndrome.

  1980cited by this paper
• Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis.

  1979cited by this paper
• Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer.

  1978cited by this paper
• Urinary 5 alpha-androstane-3 alpha,17 beta-diol radioimmunoassay: a new clinical evaluation.

  1978cited by this paper
• Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women.

  1978cited by this paper
• Pharmacology and Potential Use of Cyproterone Acetate*

  1977cited by this paper
• Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol.

  1976cited by this paper
• Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism.

  1975cited by this paper
• Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.

  1975cited by this paper
• Biologic and biochemical effects of anti-androgens on rat ventral prostate.

  1974cited by this paper
• Clinical assessment of body hair growth in women.

  1961cited by this paper

• Cyproterone acetate for hirsutism.

  2025cites this paper
• Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women

  2025cites this paper
• Potential Therapeutic Options and Perspectives for Alleviation of Endometrial Estrogen Dominance and Progesterone Resistance in Endometriosis

  2021influential citation
• Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure

  2020cites this paper
• The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

  2017cites this paper
• Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments

  2016cites this paper
• Interventions for hirsutism (excluding laser and photoepilation therapy alone).

  2015cites this paper
• Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.

  2014cites this paper
• GnRH Agonists and Antagonists

  2012cites this paper
• An approach to the patient with hirsutism.

  2012cites this paper
• Polycystic Ovary Syndrome: Update on Treatment Options and Treatment Considerations for the Future

  2011cites this paper
• Anti-androgen treatments.

  2010cites this paper
• Consensus de la société française d ’ endocrinologie sur l ’ hyperandrogénie féminine Les traitements anti-androgènes Antiandrogen treatments

  2010cites this paper
• Consensus of the French Endocrine Society on female hyperandrogenism Antiandrogen Treatments Traitements anti-androgènes

  2010cites this paper
• Les traitements anti-androgènes

  2010cites this paper
• [Etiological diagnosis of hirsutism and implications for the treatment].

  2009cites this paper
• Subfertile female androgen receptor knockout mice exhibit defects in neuroendocrine signaling, intraovarian function, and uterine development but not uterine function.

  2009cites this paper
• Alteraciones neuroendocrinas del síndrome de poliquistosis ovárica en la adolescencia

  2008cites this paper
• gonadotropin-releasing hormone analogues

  2006cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2006cites this paper
• Hommage à Andrew V. Schally

  2005cites this paper
• [Tribute to Andrew V. Schally].

  2005cites this paper
• Gonadotrophin‐releasing hormone analogues for hirsutism

  2005cites this paper
• PERCEIVED EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN: AN INTERNET PILOT STUDY

  2003cites this paper
• Cyproterone acetate for hirsutism.

  2003cites this paper
• Revisitando o Hirsutismo

  2002cites this paper
• Adult polycystic ovary syndrome begins in childhood.

  2002cites this paper
• Dermatoses of the facial skin: unapproved treatments.

  2002cites this paper
• Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome.

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions.

  2000cites this paper
• Pathogenesis of polycystic ovary syndrome: Evidence for a genetically determined disorder of ovarian androgen production

  2000cites this paper
• Spironolactone as a single agent for long‐term therapy of hirsute patients

  2000cites this paper
• SPIRONOLACTONE, BUT NOT FLUTAMIDE, ADMINISTRATION PREVENTS BONE LOSS IN HYPERANDROGENIC WOMEN TREATED WITH GONADOTROPIN-RELEASING HORMONE AGONIST

  1999cites this paper
• Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.

  1999cites this paper
• Clinical, Hormonal, and Radiological Studies at Baseline, During and After Long Term GnRH Analog (Leuprolide) Treatment in Adolescent Hirsute Females with Increased Ovarian Androgen Production Due to Polycystic Ovary Syndrome

  1999cites this paper
• Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis

  1999cites this paper
• Polycystic ovary syndrome.

  1998cites this paper
• GnRH agonists and add‐back therapy: is there a perfect combination?

  1998cites this paper
• Apoptosis and expression of apoptotic regulators in the human testis following short- and long-term anti-androgen treatment.

  1998cites this paper
• Hirsutes II: Treatment

  1998cites this paper
• Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome

  1998cites this paper
• Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome

  1997cites this paper
• Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans.

  1997cites this paper
• Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission.

  1997cites this paper
• Gilbert ( DHEA ) in Humans Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone

  1997cites this paper
• The clinical management of hirsutism.

  1997cites this paper
• A case of severe hyperandrogenism, acanthosis nigricans and over diabetes: the use of non-invasive methods for diagnosis, pathogenesis and management.

  1996cites this paper
• High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.

  1996cites this paper
• Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene.

  1996cites this paper
• ANTIANDROGEN THERAPY IN DERMATOLOGY

  1996cites this paper
• Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.

  1996cites this paper
• Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha.

  1996cites this paper
• The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor.

  1996cites this paper
• Pituitary function, ovarian follicular growth, and plasma concentrations of 17 beta-estradiol and progesterone in prepubertal heifers during and after treatment with the luteinizing hormone-releasing hormone agonist deslorelin.

  1996cites this paper
• Gonadotropin Releasing Hormone Treatment

  1996cites this paper
• Antiandrogen and hormonal treatment of acne.

  1996cites this paper
• Treatment of endometriosis with cyproterone acetate. Preliminary report.

  1996cites this paper
• Gonadotropin-releasing hormone (GnRH) agonists and estrogen/progestin replacement for the treatment of hirsutism: evaluating the results.

  1995cites this paper
• Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

  1995cites this paper
• [Polycystic ovarian dystrophies. Diagnostic criteria and treatment].

  1995cites this paper
• Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.

  1995cites this paper
• Polycystic ovary syndrome.

  1995cites this paper
• Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal "add-back" paradigms.

  1995cites this paper
• Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.

  1994cites this paper
• Octreotide Effect on Ovarian Morphology in Insulin‐Resistant PCOS Patients Following Six‐Month Decapeptyl Treatment

  1994cites this paper
• Efficacy of chronic therapy with the gonadotrophin releasing hormone agonist decapeptyl in patients with polycystic ovary syndrome.

  1994cites this paper
• Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.

  1994cites this paper
• Plasma 3 beta-hydroxy-delta 5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

  1994cites this paper
• Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and nonsteroidal agents.

  1994cites this paper
• The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism.

  1994cites this paper
• The impact of a pure anti‐androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism

  1993cites this paper
• Therapeutic Use of Gonadotropin‐Releasing Hormone Agonists in Polycystic Ovarian Syndrome

  1993cites this paper
• Use of Gonadotropin-Releasing Hormone Agonists in the Treatment of Hyperandrogenism

  1993cites this paper
• Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a d‐tr‐6‐lhrh analog

  1993cites this paper
• GnRH Agonists: Hirsutism and Hyperandrogenism

  1993cites this paper
• GnRH Agonists in the Treatment of Hyperandrogenism

  1993cites this paper
• Management of pituitary gonadal function via gonadotrophin releasing hormone (GnRH) antagonists, including ovulation induction by co-administration of either gonadotrophins or pulsatile GnRH.

  1993cites this paper
• Effects of an Oral Contraceptive Containing Cyproterone Acetate (Diane‐35) on the Symptoms, Hormone Profile, and Ovarian Volume of Hirsute Women with Polycystic Ovarian Syndrome

  1993cites this paper
• Hirsutism and Virilism

  1993cites this paper
• 3 GnRH agonists and antagonists in assisted reproduction

  1992cites this paper
• The incidence of late‐onset congenital adrenal hyperplasia due to 3β‐hydroxysteroid dehydrogenase deficiency among hirsute women

  1992cites this paper
• Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.

  1992cites this paper
• Progesterone stimulates luteinizing hormone secretion by acting directly on the pituitary.

  1992cites this paper
• Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR.

  1992cites this paper
• GnRH agonists and antagonists in assisted reproduction.

  1992cites this paper
• Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.

  1992cites this paper
• GnRH Antagonists: Primate Models for Clinical Indications

  1992cites this paper
• GNRH (Gonadotropin Salgılatıcı Hormon) Analoglarının Klinik Kullanımı)

  1991cites this paper
• Treatment of Hirsutism

  1991cites this paper
• Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and α‐subunit in postmenopausal women *

  1991cites this paper
• Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.

  1990cites this paper
• Ketoconazole use in the treatment of ovarian hyperandrogenism.

  1990cites this paper
• Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.

  1990cites this paper
• Study of the source(s) of hyperandrogenism in women with idiopathic hirsutism.

  1990cites this paper
• Study of the Source(s) of Hyperandrogenism in Women with Idiopathic Hirsutism

  1990cites this paper
• Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome.

  1990cites this paper
• Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease

  1990cites this paper
• Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.

  1990cites this paper
• Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.

  1989cites this paper